Zacks Rating on TrovaGene (TROV)

TrovaGene (TROV) has an average broker rating of 1.67, which is interpreted as a Buy, as rated by 3 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

TrovaGene (TROV) : 3 Wall Street analysts covering TrovaGene (TROV) believe that the average level the stock could reach for the short term is $7. The maximum price target given is $9 and the minimum target for short term is around $4, hence the standard deviation is calculated at $2.65.


TrovaGene, Inc. has dropped 6.8% in the last five trading days, however, the shares have posted positive gains of 1.56% in the last 4 weeks. TrovaGene, Inc. has dropped 1.51% during the last 3-month period . Year-to-Date the stock performance stands at -3.52%. TrovaGene (NASDAQ:TROV): On Tuesdays trading session , Opening price of the stock was $5.41 with an intraday high of $5.47. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $5.15. However, the stock managed to close at $5.21, a loss of 3.70% for the day. On the previous day, the stock had closed at $5.41. The total traded volume of the day was 346,914 shares.

Trovagene, Inc. is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Companys primary internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. Its cell-free BRAF test confirms the presence of a BRAF V600E mutation in urine DNA at levels of greater than or equal to 0.03% in comparison to the wild-type BRAF genes. Its KRAS mutation assay detects and monitors the seven commonly encountered mutations of the KRAS oncogene. Its urine-based Human Papilloma Virus (HPV) assay identifies women with high grade cervical intraepithelial neoplasia (CIN2/3).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.